Homepage Bottom Left

Committed BC health care providers receive two awards

Wendy Quinn | 22/04/2022

by Wendy Quinn, CHS President A few days ago I received an e-mail with the subject “Exciting news and accomplishments in BC.” I immediately opened...

CBS supplier contracts for rFVIII and rFIX take effect April 4

David Page | 30/03/2022

March 30, 2022, Ottawa – Canadian Blood Services’ contracts with suppliers of recombinant factor VIII and IX for the 2022-2025 period take effect on April...

The 10 key takeaways from CHS advocacy efforts to obtain access to emicizumab (Hemlibra)

David Page | 16/03/2022

by David Page, CHS National Director of Health Policy The Canadian Hemophilia Society (CHS), its chapters and members have expended great efforts to advocate for...

Update on products in the pipeline

David Page | 09/03/2022

Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates, inhibitor...

Hemlibra approved for all those with severe hemophilia A in Quebec – Access starts April 1

David Page | 01/03/2022

by David Page, CHS National Director of Health Policy March 1, 2022, Montréal – The Canadian Hemophilia Society (CHS) was informed yesterday by Héma-Québec that access...